Finally, in glioblastoma, interferon signaling may be abrogated, such that the tumor often exhibits defective responses to IFN-γ signaling, even when the ligand binds to its receptor, which may facilitate immune evasion or even promote tumor growth. This evidence concerns the gene IFNG and glioblastoma.